Variable regions for NKp46 binding proteins

Patent metadata

Field	Value
Publication number	US-11891444-B2
Application number	US-202117315547-A
Country	US
Kind code	B2
Filing date	May 10, 2021
Priority date	Dec 28, 2015
Publication date	Feb 6, 2024
Grant date	Feb 6, 2024

Abstract

NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

First claim

We claim:

1. An isolated nucleic acid encoding a heavy chain variable region (VH) and/or a light chain variable region (VL) selected from the group consisting of:
(a) a VH comprising an amino acid sequence of SEQ ID NOS: 199 or 200 (NKp46-1 H1 or H3 variable domain), and a VL comprising an amino acid sequence of the amino acid sequence of SEQ ID NO: 201 (NKp46-1 L1 variable domain);
(b) a VH comprising an amino acid sequence of SEQ ID NOS: 202, 203 or 204 (NKp46-2 H1, H2 or H3 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 205 (NKp46-2 L1 variable domain);
(c) a VH comprising an amino acid sequence of SEQ ID NOS: 206, 207 or 208 (NKp46-3 H1, H3 or H4 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 209 (NKp46-3 L1 variable domain);
(d) a VH comprising an amino acid sequence of SEQ ID NOS: 210, 211 or 212 (NKp46-4 H1 variable domain), and a VL comprising an amino acid sequence of SEQ ID NO: 213 (NKp46-4 L2 variable domain);
(e) a VH comprising an amino acid sequence of SEQ ID NO: 215 (NKp46-9 H2 variable domain), and a VL comprising an amino acid sequence of SEQ ID NOS: 217 or 218 (NKp46-9 L1 or L2 variable domain); or
(f) a VH comprising an amino acid sequence of SEQ ID NO: 216 (NKp46-9 H3 variable domain), and a VL comprising an amino acid sequence of SEQ ID NOS: 217 or 218 (NKp46-9 L1 or L2 variable domain).

2. A recombinant host cell comprising a nucleic acid according to claim 1 .

3. A method of producing a protein comprising culturing a cell of claim 2 under conditions suitable for expression of the protein and recovering the protein.

4. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NOS: 199 or 200.

5. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NO: 201.

6. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NOS: 202, 203 or 204.

7. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NO: 205.

8. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NOS: 206, 207 or 208.

9. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NO: 209.

10. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NOS: 210, 211 or 212.

11. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NO: 213.

12. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NO: 215.

13. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NOS: 217 or 218.

14. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VH comprising SEQ ID NO: 216.

15. The nucleic acid according to claim 1 , wherein said nucleic acid encodes a VL comprising SEQ ID NOS: 217 or 218.

Assignees

• Innate Pharma

Inventors

• Gauthier Laurent
• Anceriz Nadia
• Morel Ariane
• Rossi Benjamin

Classifications

• C07K16/2803 Primary

  against the immunoglobulin superfamily · CPC title

• C07K16/2809

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/2887

  against CD20 · CPC title

• C07K16/468

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title

• C12N5/10

  Cells modified by introduction of foreign genetic material · CPC title